11.10.2026, 15:00
Einladung zur Festlichen Bläsermusik
15.10.2026, 15:00
Forschung in echt: Austausch macht Schule – Vertrauen stärken, Urteilskraft fördern
Wie können wir junge Menschen darin stärken, wissenschaftliche Informationen kritisch einzuordnen und fundierte Entscheidungen zu treffen? Am Beispiel der HPV-Impfung haben wir in dem Projekt Besuch...
more ...
15.10.2026, 17:00
Talk im Cube: Entrepreneurship Programs & Business Plan Development for Life Scientists
Join us for this edition of Talk in the Cube to explore - how life scientists can leverage entrepreneurship programs and - robust business plans that address market opportunities, regulatory requireme...
more ...
T-knife Therapeutics is one of the most successful start-ups in the biotech scene. Founded in 2018 as a spin-off of the Max Delbrück Center for Molecular Medicine (MDC) with the support of Charité – Universitätsmedizin Berlin, its mission is to develop therapies that can combat cancer with the help of patients’ immune systems. Over the course of many years, the research team led by Professor Thomas Blankenstein has worked towards genetically modifying human T cells in such a way that their receptors can target and destroy specific tumor cells. Using this unique technology, the first T-cell receptor gene therapy in Germany is now being tested in a clinical trial.
The prospect that the first clinical trials will lead to the successful treatment of patients inspires and motivates the team of OMEICOS Therapeutics GmbH. All previous data suggest that the scientists and founders have for the first time found a
